Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 1/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.43 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.43 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4879314 | 0.87 | MAPK1 (0.44) | GAAALDH1A1 | |
| SCHEMBL13886757 | 0.84 | PTGS1 (0.50) | GAAALDH1A1AKR1C3AKR1C1 | |
| SCHEMBL4449688 | 0.84 | PTGS1 (0.50) | GAAALDH1A1AKR1C3AKR1C1 | |
| SCHEMBL5055339 | 0.84 | ALDH1A1 (0.58) | GAACA4ALDH1A1AKR1C3AKR1C1 | |
| SCHEMBL17466002 | 0.80 | ALDH1A1 (0.48) | CASRAOC3ALDH1A1L3MBTL1NPC1 | |
| SCHEMBL954319 | 0.79 | CASR (0.46) | CASRAOC3ALDH1A1L3MBTL1ACHE | |
| SCHEMBL30835603 | 0.78 | FGFR2 (0.44) | AOC3NAAANPC1RAB9A | |
| SCHEMBL11984338 | 0.78 | ALDH1A1 (0.49) | CASRMTNR1AMTNR1BGAAAOC3 | |
| SCHEMBL8747263 | 0.77 | AOC3 (0.44) | CASRAOC3ALDH1A1NAAAL3MBTL1 | |
| SCHEMBL28782471 | 0.77 | KMT2A (0.45) | CASRAOC3ALDH1A1PBRM1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109222100-A | A kind of ginseng Cordyceps militaris composition, ginseng Cordyceps militaris pressed candy and preparation method thereof | 上海屹泽生物科技有限公司 | 2019-01-18 | — | — | CN | disclosed |
| US-9777069-B2 | Compositions and methods for detection of methadone metabolite | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2017-10-03 | — | — | US | disclosed |
| EP-2121594-B1 | QUATERNARY AMMONIUM DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R & D IP LLC (US) | 2015-10-21 | — | — | EP | disclosed |
| EP-2121594-B1 | QUATERNARY AMMONIUM DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R & D IP LLC (US) | 2015-10-21 | — | — | EP | disclosed |
| EP-2810072-A1 | COMPOSITIONS AND METHODS FOR DETECTION OF METHODONE METABOLITE | Siemens Healthcare Diagnostics Inc. (US) | 2014-12-10 | — | — | EP | disclosed |
| US-8802856-B2 | Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802856-B2 | Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802856-B2 | Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-08-12 | — | — | US | disclosed |
| US-20140221626-A1 | COMPOSITIONS AND METHODS FOR DETECTION OF METHADONE METABOLITE | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8771964-B2 | Compositions and methods for detection of methadone metabolite | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20110020231-A1 | QUATERNARY AMMONIUM DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-7834185-B2 | Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834185-B2 | Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834185-B2 | Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| EP-2121594-A1 | QUATERNARY AMMONIUM DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080207736-A1 | Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-08-28 | — | — | US | disclosed |
| WO-2008103426-A1 | QUATERNARY AMMONIUM DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2008-08-28 | — | — | WO | disclosed |
| US-20080207736-A1 | Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-08-28 | — | — | US | disclosed |
| US-20080207736-A1 | Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-08-28 | — | — | US | disclosed |
| WO-2008103426-A1 | QUATERNARY AMMONIUM DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221626-A1 | COMPOSITIONS AND METHODS FOR DETECTION OF METHADONE METABOLITE | DNPEP, OPRD1, NPEPPS | CASR 4463/4885MTNR1A 1229/4885MTNR1B 1037/4885 |
| US-20080207736-A1 | Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM5, CHRM1 | CASR 297/4885MTNR1A 184/4885MTNR1B 119/4885 |
| US-20110020231-A1 | QUATERNARY AMMONIUM DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM5, CHRM1 | CASR 297/4885MTNR1A 184/4885MTNR1B 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.